MOCETINOSTAT

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C23H20N6O
Molecular Weight	396.4445
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NC1=CC=CC=C1NC(=O)C2=CC=C(CNC3=NC(=CC=N3)C4=CC=CN=C4)C=C2

InChI

InChIKey=HRNLUBSXIHFDHP-UHFFFAOYSA-N

InChI=1S/C23H20N6O/c24-19-5-1-2-6-21(19)28-22(30)17-9-7-16(8-10-17)14-27-23-26-13-11-20(29-23)18-4-3-12-25-15-18/h1-13,15H,14,24H2,(H,28,30)(H,26,27,29)

HIDE SMILES / InChI

Molecular Formula	C23H20N6O
Molecular Weight	396.4445
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=486941
Curator's Comment: description was created based on several sources, including: http://adisinsight.springer.com/drugs/800020983 | http://mirati.com/programs/mocetinostat/ | http://meetinglibrary.asco.org/content/117882-132

Mocetinostat is an rationally designed, orally available, Class 1-selective, small molecule, 2-aminobenzamide HDAC inhibitor with potential antineoplastic activity. Mocetinostat binds to and inhibits Class 1 isoforms of HDAC, specifically HDAC 1, 2 and 3, which may result in epigenetic changes in tumor cells and so tumor cell death; although the exact mechanism has yet to be defined, tumor cell death may occur through the induction of apoptosis, differentiation, cell cycle arrest, inhibition of DNA repair, upregulation of tumor suppressors, down regulation of growth factors, oxidative stress, and autophagy, among others. It is undergoing clinical trials for treatment of various cancers including bladder cancer, diffuse large B cell lymphoma, follicular lymphoma, myelodysplastic syndromes, non-small cell lung cancer. Fatigue, weight loss or anorexia were most common treatment-related adverse events.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Histone deacetylase 1 51 Target ID: CHEMBL325 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18413790	Inhibitor 8504	0.15 µM [IC50]
Histone deacetylase 2 37 Target ID: CHEMBL1937 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18413790	Inhibitor 8504	0.29 µM [IC50]
Histone deacetylase 3 35 Target ID: CHEMBL1829 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18413790	Inhibitor 8504	1.66 µM [IC50]
Histone deacetylase 11 7 Target ID: CHEMBL3310 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18413790	Inhibitor 8504	0.59 µM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Chronic lymphocytic leukemia 59 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19747365	Primary	Phase II 1147	Unknown Approved Use Unknown
Myelodysplastic syndromes 61 Sources: http://adisinsight.springer.com/drugs/800020983 https://clinicaltrials.gov/ct2/show/NCT02018926	Primary	Phase II 1147	Unknown Approved Use Unknown
Non-small cell lung cancer 211 Sources: http://mirati.com/programs/mocetinostat/ http://adisinsight.springer.com/drugs/800020983	Primary	Phase II 1147	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
161 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/18495956	60 mg/m² single, oral dose: 60 mg/m² route of administration: Oral experiment type: SINGLE co-administered:		MOCETINOSTAT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
1000 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/18495956	60 mg/m² single, oral dose: 60 mg/m² route of administration: Oral experiment type: SINGLE co-administered:		MOCETINOSTAT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
10.9 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/18495956	60 mg/m² single, oral dose: 60 mg/m² route of administration: Oral experiment type: SINGLE co-administered:		MOCETINOSTAT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
110 mg 3 times / week multiple, oral Highest studied dose Dose: 110 mg, 3 times / week Route: oral Route: multiple Dose: 110 mg, 3 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/22033282	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/22033282	Disc. AE: Neutropenic infection... AEs leading to discontinuation/dose reduction: Neutropenic infection (grade 5, 4.3%) Sources: https://pubmed.ncbi.nlm.nih.gov/22033282
110 mg 3 times / week multiple, oral Highest studied dose Dose: 110 mg, 3 times / week Route: oral Route: multiple Dose: 110 mg, 3 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/29238851	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/29238851	DLT: Nausea, Vomiting... Dose limiting toxicities: Nausea (grade 3, 25%) Vomiting (grade 3, 25%) Abdominal pain (grade 3, 25%) Diarrhea (grade 3, 25%) Fatigue (grade 3, 25%) Fatigue (grade 4, 25%) Deep vein thrombosis (grade 3, 25%) Mental status changes (grade 3, 25%) Sources: https://pubmed.ncbi.nlm.nih.gov/29238851
90 mg 3 times / day multiple, oral MTD Dose: 90 mg, 3 times / day Route: oral Route: multiple Dose: 90 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29238851	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/29238851	Sources: https://pubmed.ncbi.nlm.nih.gov/29238851

AEs

AE	Significance	Dose	Population
Neutropenic infection	grade 5, 4.3% Disc. AE	110 mg 3 times / week multiple, oral Highest studied dose Dose: 110 mg, 3 times / week Route: oral Route: multiple Dose: 110 mg, 3 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/22033282	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/22033282
Abdominal pain	grade 3, 25% DLT	110 mg 3 times / week multiple, oral Highest studied dose Dose: 110 mg, 3 times / week Route: oral Route: multiple Dose: 110 mg, 3 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/29238851	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/29238851
Deep vein thrombosis	grade 3, 25% DLT	110 mg 3 times / week multiple, oral Highest studied dose Dose: 110 mg, 3 times / week Route: oral Route: multiple Dose: 110 mg, 3 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/29238851	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/29238851
Diarrhea	grade 3, 25% DLT	110 mg 3 times / week multiple, oral Highest studied dose Dose: 110 mg, 3 times / week Route: oral Route: multiple Dose: 110 mg, 3 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/29238851	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/29238851
Fatigue	grade 3, 25% DLT	110 mg 3 times / week multiple, oral Highest studied dose Dose: 110 mg, 3 times / week Route: oral Route: multiple Dose: 110 mg, 3 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/29238851	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/29238851
Mental status changes	grade 3, 25% DLT	110 mg 3 times / week multiple, oral Highest studied dose Dose: 110 mg, 3 times / week Route: oral Route: multiple Dose: 110 mg, 3 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/29238851	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/29238851
Nausea	grade 3, 25% DLT	110 mg 3 times / week multiple, oral Highest studied dose Dose: 110 mg, 3 times / week Route: oral Route: multiple Dose: 110 mg, 3 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/29238851	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/29238851
Vomiting	grade 3, 25% DLT	110 mg 3 times / week multiple, oral Highest studied dose Dose: 110 mg, 3 times / week Route: oral Route: multiple Dose: 110 mg, 3 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/29238851	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/29238851
Fatigue	grade 4, 25% DLT	110 mg 3 times / week multiple, oral Highest studied dose Dose: 110 mg, 3 times / week Route: oral Route: multiple Dose: 110 mg, 3 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/29238851	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/29238851

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY116244	https://www.001chemical.com/chem/search?q=DY116244
1PlusChem LLC	1P0039R9	https://www.1pchem.com/search?query=1P0039R9
A2B Chem	AB51813	http://a2bchem.com/prod/AB51813
AK Scientific	X7532	https://aksci.com/item_detail.php?cat=X7532
Ambeed	A102453	http://www.ambeed.com/search/Search.html?keyword=A102453
Angene	AGN-PC-0MUSW4	http://www.angenechemical.com/productshow/AGN-PC-0MUSW4.html
AOBIOUS INC	AOB87751	http://aobious.com/aobious/search?search_query=AOB87751
ApexBio Technology	A4089	https://www.apexbt.com/catalogsearch/result/?q=A4089
AstaTech	40645	http://astatechinc.com/CPSResult.php?CRNO=40645
Axon MedChem	2505	https://www.axonmedchem.com/product/2505
BLD Pharm	BD305950	http://www.bldpharm.com/search/Search.html?keyword=BD305950
BOC Sciences	726169-73-9	http://www.bocsci.com/description.asp?cas=726169-73-9
Capot Chemical	24623	https://www.capotchem.com/search.do?q=24623
Cayman Chemical	18287	http://www.caymanchem.com/app/template/Product.vm/catalog/18287
Chem Scene	CS-0502	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-0502
ChemShuttle	101210	https://www.chemshuttle.com/catalogsearch/result/?q=101210
eMolecules	32176474	https://orderbb.emolecules.com/search/#?query=32176474
eMolecules	85163381	https://orderbb.emolecules.com/search/#?query=85163381
eNovation Chemicals	D619806	https://www.enovationchem.com/Products.asp?SEARCHTEXT=D619806&searchbtn.x=0&searchbtn.y=0
Excenen	EX-A049	http://www.excenen.com/searchresultlist.php?id=EX-A049
Exclusive Chemistry	2284	http://www.exchemistry.com/chem-catalog/product-2284.html
KeyOrganics	BD-0114	http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=BD-0114
Lab Network	LN01306423	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01306423
Lab Seeker	SC-85911	http://www.labseeker.com/search.php?keywords=SC-85911&category=0
LabSeeker	SC-85911	http://www.labseeker.com/search.php?keywords=SC-85911&category=0
Matrix Scientific	143829	http://www.matrixscientific.com/143829.html
mcule	MCULE-2367278974	https://mcule.com/MCULE-2367278974/
mcule	MCULE-4492645927	https://mcule.com/MCULE-4492645927/
MedChem Express	HY-12164	https://www.medchemexpress.com/search.html?q=HY-12164&ft=&fa=&fp=
Molcore	MC116244	http://www.molcore.com/CatMC116244.html
Molnova	M15781	https://www.molnova.com/en/serch-list.html?keywords=M15781
MolPort	MolPort-009-679-400	https://www.molport.com/shop/molecule-link/MolPort-009-679-400
MuseChem	I004705	https://www.musechem.com/product/I004705.html
Ryan Scientific	Macitentan	https://ryansci.com/products?q=Macitentan&list_q=&search_type=exact
ShangHai Biochempartner	BCP000119	http://www.biochempartner.com/search_BCP000119
ShangHai Biochempartner	BCP01814	http://www.biochempartner.com/search_BCP01814
TargetMol	T2512	https://www.targetmol.com/search?keyword=T2512
Toronto Research Chemicals	D435235	https://www.trc-canada.com/product-detail/?CatNum=D435235
Toronto Research Chemicals	M481090	https://www.trc-canada.com/product-detail/?CatNum=M481090

PubMed

Title	Date	PubMed
Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay.	2008 Jun 1	18519775
Histone deacetylase inhibitors in lymphoma and solid malignancies.	2008 Mar	18366289
New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer.	2009 Jun 1	19486511
Chemical phylogenetics of histone deacetylases.	2010 Mar	20139990
Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors.	2011 Jul 14	21650221
Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103.	2011 May	21171821
Natural indoles, indole-3-carbinol and 3,3'-diindolymethane, inhibit T cell activation by staphylococcal enterotoxin B through epigenetic regulation involving HDAC expression.	2014 Jan 1	24200994

Patents

Sample Use Guides

In Vivo Use Guide

Starting dose of 85 mg three times per week for four weeks. Dose escalation to 110 mg three times per week was permitted beginning with cycle 2 in patients who failed to achieve a complete response.

Route of Administration: Oral

In Vitro Use Guide

The inhibitory activity of MGCD0103 reaches the maximum plateau at 6 μM, and the maximal inhibitable enzyme pool affected by MGCD0103 is 75% of the total enzyme activity in HCT116 cells.

Substance Class	Chemical Created by `admin` on `Wed Apr 02 09:19:36 GMT 2025` Edited by `admin` on `Wed Apr 02 09:19:36 GMT 2025`
Record UNII	A6GWB8T96J
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MGCD-0103

Preferred Name

English

MOCETINOSTAT

Official Name

English

BENZAMIDE, N-(2-AMINOPHENYL)-4-(((4-(3-PYRIDINYL)-2-PYRIMIDINYL)AMINO)METHYL)-

Systematic Name

English

Mocetinostat [WHO-DD]

Common Name

English

mocetinostat [INN]

Common Name

English

N-(2-Aminophenyl)-4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzamide

Systematic Name

English

MOCETINOSTAT [USAN]

Common Name

English

MGCD0103

Code

English

Classification Tree Code System Code

EU-Orphan Drug

EU/3/07/526